Honoured to be there! Let’s make of #ESMO24 the best scientific meeting ever

Global issues ➡️ global solutions 🌍 #ESMOYOC is key to addressing the needs of #YoungOncologists. Matteo Lambertini, MD PhD Angelika Starzer Deniz Can Guven Elene Mariamidze Emre Kocakavuk, MD, PhD Hongcheng Zhu 祝鸿程 Liz Connolly Maria Kfoury Myrto K. Moutafi Pablo Mando Pawel Sobczuk Rille Rodrigo Sánchez-Bayona

Palabra por palabra 👏🏻👏🏻👏🏻👏🏻👏🏻

The main reason for coming to ESMO: working with friends on something that surpasses us and generates a legacy ESMO - Eur. Oncology #ESMO24 #ESMOYOC Rodrigo Sánchez-Bayona Pawel Sobczuk Rille Liz Connolly Elene Mariamidze Maria Kfoury Deniz Can Guven Hongcheng Zhu 祝鸿程 Myrto K. Moutafi Angelika Starzer

#ESMO24 Congress Programme numbers are really breathtaking! The result of a global community’s commitment to fighting cancer #ESMOAmbassadors ESMO - Eur. Oncology

Live now at #ESMO24, the results of the DESTINYBreast12 trial. Prospective solid evidence that TDXd is effective in patients with BMs #ESMOAmbassadors ESMO - Eur. Oncology

Considering the efficacy results of TDXd in DestinyBreast12 trial, would you say that TDXd is the standard second line in HER2+ MBC irrespective of BM? ESMO - Eur. Oncology #ESMOAmbassadors #ESMO24

EBC Mini-oral session at #ESMO24 now Impressive results of the new genomic test TNBC-DX for patients with stage I-III, associated with DDFS and OS ESMO - Eur. Oncology #ESMOAmbassadors

Young oncologists rocking on GYN cancer 🚀🚀 Results of Phase I study with new anti-folate receptor alpha ADC in recurrent HGSOC presented by Ainhoa Madariaga #ESMO24 #ESMOAmbassadors ESMO - Eur. Oncology

Great discussion now at YO Brunch session about NGS in cancer 👨🏼‍🏫🧬🔬 Terrific faculty with Ben Westphalen Pawel Sobczuk Rille ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors

‼️ NOT TO BE MISSED YO MASTERCLASS STARTING SOON ‼️ Everything you need to know 💫 Designing v2.0 clinical trials With Ruth Ines Vaz Luis ⏰ 14:45-17:45 📍Cartagena-HalL #ESMOYOC #ESMO2024

We did it! KN522 trial demonstrates an OS benefit with pembrolizumab + NACT in TN eBC It’s encouraging to see what we, as Oncology community, can achieve ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors

With the 4y-update of NATALEE trial, would you consider treating patients with stage II HR+/HER2- eBC with adjuvant ribociclib? #ESMO24 ESMO - Eur. Oncology #ESMOAmbassadors Paolo Tarantino

And that's a wrap 🌯 for the #ESMO24 young oncologist track! Such a joy chairing this ❤️🤩 , soo grateful for all the excellent world class speakers and the YOC members for giving their absolute best!! Bigger conclusions coming later, need first some ⛱️☀️🌊🍦🍹

Final tweet from #ESMO24 to acknowledge the super work of the Young Oncologists Committee and to celebrate the success of the #ESMOYOC track…a real privilege to have had the chance to serve this fantastic group over the past years ❤️🤩👏🔝 ESMO - Eur. Oncology #ESMOAmbassadors OncoAlert

📊 Interesting results on this poll about stage II BC and adjuvant ribociclib 46% of participants would give it irrespective of nodal involvement ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors

Te has inscrito ya? 👀SOLTIyoung ofrece una beca para asistir al congreso SABCS2024 en San Antonio, incluyendo inscripción, traslado y manutención. Bases en gruposolti.org/soltiyoung/ #beSOLTI #cancerdemama